SGIOY Quote, Financials, Valuation and Earnings

PeptiDream has a net margin of 42.36% compared to Shionogi &'s net margin of -24.41%. Shionogi &'s return on equity of 12.79% beat PeptiDream's return on equity of 34.1%.

Shionogi & has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Shionogi & has higher upside potential than PeptiDream, analysts believe Shionogi & is more attractive than PeptiDream.

Shionogi & has a beta of 0.270, which suggesting that the stock is 73.019% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.312%.

Shionogi & has a quarterly dividend of $0.09 per share corresponding to a yield of 2.2%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shionogi & pays 28.57% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Shionogi &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Shionogi & quarterly revenues are $784.3M, which are larger than PeptiDream quarterly revenues of $27.8M. Shionogi &'s net income of $332.2M is higher than PeptiDream's net income of -$6.8M. Notably, Shionogi &'s price-to-earnings ratio is 18.60x while PeptiDream's PE ratio is 16.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shionogi & is 9.70x versus 5.80x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of 42.36% compared to Shionogi &'s net margin of -11.44%. Shionogi &'s return on equity of 12.79% beat Nxera Pharma's return on equity of -8.65%.

Shionogi & has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Shionogi & has higher upside potential than Nxera Pharma, analysts believe Shionogi & is more attractive than Nxera Pharma.

Shionogi & has a beta of 0.270, which suggesting that the stock is 73.019% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.648%.

Shionogi & has a quarterly dividend of $0.09 per share corresponding to a yield of 2.2%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shionogi & pays 28.57% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Shionogi &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Shionogi & quarterly revenues are $784.3M, which are larger than Nxera Pharma quarterly revenues of $43.6M. Shionogi &'s net income of $332.2M is higher than Nxera Pharma's net income of -$5M. Notably, Shionogi &'s price-to-earnings ratio is 18.60x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shionogi & is 9.70x versus 2.76x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of 42.36% compared to Shionogi &'s net margin of -9.79%. Shionogi &'s return on equity of 12.79% beat Takeda Pharmaceutical's return on equity of 1.49%.

Shionogi & has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.31 which suggests that it could grow by 17.97%. Given that Takeda Pharmaceutical has higher upside potential than Shionogi &, analysts believe Takeda Pharmaceutical is more attractive than Shionogi &.

Shionogi & has a beta of 0.270, which suggesting that the stock is 73.019% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.114%.

Shionogi & has a quarterly dividend of $0.09 per share corresponding to a yield of 2.2%. Takeda Pharmaceutical offers a yield of 4.22% to investors and pays a quarterly dividend of $0.33 per share. Shionogi & pays 28.57% of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend. Shionogi &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

Shionogi & quarterly revenues are $784.3M, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. Shionogi &'s net income of $332.2M is higher than Takeda Pharmaceutical's net income of -$676.5M. Notably, Shionogi &'s price-to-earnings ratio is 18.60x while Takeda Pharmaceutical's PE ratio is 67.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shionogi & is 9.70x versus 1.57x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Torii Pharmaceutical has a net margin of 42.36% compared to Shionogi &'s net margin of 9.47%. Shionogi &'s return on equity of 12.79% beat Torii Pharmaceutical's return on equity of 4.45%.

Shionogi & has a consensus price target of --, signalling downside risk potential of --. On the other hand Torii Pharmaceutical has an analysts' consensus of -- which suggests that it could fall by --. Given that Shionogi & has higher upside potential than Torii Pharmaceutical, analysts believe Shionogi & is more attractive than Torii Pharmaceutical.

Shionogi & has a beta of 0.270, which suggesting that the stock is 73.019% less volatile than S&P 500. In comparison Torii Pharmaceutical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Shionogi & has a quarterly dividend of $0.09 per share corresponding to a yield of 2.2%. Torii Pharmaceutical offers a yield of 3.07% to investors and pays a quarterly dividend of $0.38 per share. Shionogi & pays 28.57% of its earnings as a dividend. Torii Pharmaceutical pays out 72.47% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Shionogi & quarterly revenues are $784.3M, which are larger than Torii Pharmaceutical quarterly revenues of $96.3M. Shionogi &'s net income of $332.2M is higher than Torii Pharmaceutical's net income of $9.1M. Notably, Shionogi &'s price-to-earnings ratio is 18.60x while Torii Pharmaceutical's PE ratio is 19.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shionogi & is 9.70x versus 1.78x for Torii Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.